Dividends & Buybacks ·
Liminatus Pharma shareholders authorize reverse stock split up to 1-for-50 to meet Nasdaq rules
LIMNLiminatus Pharma, Inc.
Liminatus Pharma, Inc. held its 2026 Annual Meeting of Stockholders on August 3, 2026, where shareholders approved the ratification of Withum Smith+Brown PC as independent auditor and elected Nicholas Fernandez and Dr. Ji Yeon Baek to the Board. Crucially, stockholders authorized the Board to implement a reverse stock split at a ratio of up to 1-for-50 shares to satisfy Nasdaq listing requirements. The company operates in the biopharmaceutical industry.